Patrick Lyden

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection
    Patrick Lyden
    From the Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA P L ZZ Biotech, LLC, Houston, TX S W, H L, K P Department of Biostatistics, University of Iowa, Iowa City C C, S O Neurological Clinical Research Institute, Massachusetts General Hospital, Boston M C, S B Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA M F Department of Neurology, University of Virginia, Charlottesville E C H Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH P K Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles J S Department of Neurology, State University of New York Downstate Medical Center, Brooklyn S L Department of Neurology, University of Kansas Hospital, Kansas City M R Department of Neurology, University of Pittsburgh Medical School, PA L W, A J and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD E M, S W
    Stroke 47:2979-2985. 2016
  2. pmc Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2)
    Patrick Lyden
    From the Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA P L Department of Neurosciences T H, K R, B M and Sanford Stem Cell Clinical Center T R, University of California, San Diego Department of Neurology, Memorial Health Care System, Houston, TX J G Alzheimer s Therapeutic Research Institute, University of Southern California, San Diego K E, R R Department of Neurology, University of Texas McGovern Medical School, Houston S P Department of Neurosciences, Sarasota Memorial Health Care System, FL M C Department of Neurology, Michigan State University, Kalamazoo S H Department of Neurology, Columbia University, New York, NY S A Performance Improvement Patient Safety Department, UC San Diego Health System, CA J J and Department of Neurology, North Memorial Medical Center, Minneapolis, MN I A
    Stroke 47:2888-2895. 2016
  3. pmc Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers
    Patrick Lyden
    Department of Neurology, 8700 Beverly Blvd, Los Angeles, CA 90048
    Curr Pharm Des 19:7479-85. 2013
  4. doi request reprint Hemorrhagic transformation during thrombolytic therapy and reperfusion: effects of age, blood pressure, and matrix metalloproteinases
    Patrick D Lyden
    Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90036, USA
    J Stroke Cerebrovasc Dis 22:532-8. 2013
  5. doi request reprint Sisyphus and translational stroke research
    Patrick Lyden
    Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Sci Transl Med 4:156ps20. 2012
  6. pmc Determinants of effective cooling during endovascular hypothermia
    Patrick Lyden
    Department of Neurology, Cedars Sinai Medical Center, Thalians E240, 8730 Alden Drive, Los Angeles, CA 90048, USA
    Neurocrit Care 16:413-20. 2012
  7. doi request reprint Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage
    Brett Cucchiara
    Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Int J Stroke 6:109-11. 2011
  8. doi request reprint Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials
    Brett Cucchiara
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Stroke 40:3067-72. 2009
  9. pmc Evolution of the thrombolytic treatment window for acute ischemic stroke
    Andrew Stemer
    University of California, San Diego, Medical Office North, Third Floor, Suite 3, 200 West Arbor Drive, 8466, San Diego, CA, 92103, USA
    Curr Neurol Neurosci Rep 10:29-33. 2010
  10. pmc Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials
    Kennedy R Lees
    From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom K R L Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Nuffield Department of Population Health, University of Oxford, United Kingdom J E, L B, C B Statistics Department, Boehringer Ingelheim, Germany E B Melbourne Brain Centre, The Royal Melbourne Hospital and University of Melbourne, Australia S M D Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia G A D Mobile Stroke Unit and Stroke Research Program, Memorial Hermann Hospital, Houston, TX J C G Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland M K Department of Neuroradiology, Technische Universitat, Dresden, Germany R v K Stanford Stroke Center, Palo Alto, CA M G L Discipline of Medicine, Westmead Hospital Clinical School, George Institute For Global Health, University of Sydney, NSW, Australia R I L Department of Neurology, Cedars Sinai, Los Angeles, CA P L Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, United Kingdom G D M Centre for Clinical Brain Sciences, University of Edinburgh, Laboratory of Medical Immunology
    Stroke 47:2373-9. 2016

Research Grants

  1. Role of Angiogenesis Following Stroke
    Patrick Lyden; Fiscal Year: 2006

Collaborators

Detail Information

Publications15

  1. pmc Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection
    Patrick Lyden
    From the Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA P L ZZ Biotech, LLC, Houston, TX S W, H L, K P Department of Biostatistics, University of Iowa, Iowa City C C, S O Neurological Clinical Research Institute, Massachusetts General Hospital, Boston M C, S B Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA M F Department of Neurology, University of Virginia, Charlottesville E C H Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH P K Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles J S Department of Neurology, State University of New York Downstate Medical Center, Brooklyn S L Department of Neurology, University of Kansas Hospital, Kansas City M R Department of Neurology, University of Pittsburgh Medical School, PA L W, A J and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD E M, S W
    Stroke 47:2979-2985. 2016
    ..We sought to demonstrate feasibility of IAT in neuroprotectant trials by defining IAT selection criteria for an ongoing neuroprotectant clinical trial...
  2. pmc Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2)
    Patrick Lyden
    From the Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA P L Department of Neurosciences T H, K R, B M and Sanford Stem Cell Clinical Center T R, University of California, San Diego Department of Neurology, Memorial Health Care System, Houston, TX J G Alzheimer s Therapeutic Research Institute, University of Southern California, San Diego K E, R R Department of Neurology, University of Texas McGovern Medical School, Houston S P Department of Neurosciences, Sarasota Memorial Health Care System, FL M C Department of Neurology, Michigan State University, Kalamazoo S H Department of Neurology, Columbia University, New York, NY S A Performance Improvement Patient Safety Department, UC San Diego Health System, CA J J and Department of Neurology, North Memorial Medical Center, Minneapolis, MN I A
    Stroke 47:2888-2895. 2016
    ..Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients...
  3. pmc Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers
    Patrick Lyden
    Department of Neurology, 8700 Beverly Blvd, Los Angeles, CA 90048
    Curr Pharm Des 19:7479-85. 2013
    ..3K3A-APC was designed for preserved activity at PAR-1 with reduced anticoagulation. This Phase 1 trial characterized pharmacokinetics and anticoagulation effects of 3K3A-APC...
  4. doi request reprint Hemorrhagic transformation during thrombolytic therapy and reperfusion: effects of age, blood pressure, and matrix metalloproteinases
    Patrick D Lyden
    Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90036, USA
    J Stroke Cerebrovasc Dis 22:532-8. 2013
    ..We sought to test the effects of age, hypertension, and matrix metalloproteinases during recombinant tissue plasminogen activator (rt-PA) treatment in a standard model of filament occlusion of the middle cerebral artery...
  5. doi request reprint Sisyphus and translational stroke research
    Patrick Lyden
    Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Sci Transl Med 4:156ps20. 2012
    ..New preclinical and clinical approaches conceived outside of the current paradigm exist and should be carefully considered. Now, Tymianski and colleagues report on results obtained during translation of a new neuroprotectant...
  6. pmc Determinants of effective cooling during endovascular hypothermia
    Patrick Lyden
    Department of Neurology, Cedars Sinai Medical Center, Thalians E240, 8730 Alden Drive, Los Angeles, CA 90048, USA
    Neurocrit Care 16:413-20. 2012
    ..We demonstrated the feasibility of thrombolysis combined with endovascular hypothermia, but not all patients achieved effective cooling. We sought to identify the factors that determined effective cooling...
  7. doi request reprint Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage
    Brett Cucchiara
    Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Int J Stroke 6:109-11. 2011
    ..Two clinical risk scores, the Haemorrhage After Thrombolysis and Multicentre Stroke Survey scores, have been proposed to predict the risk of intracerebral haemorrhage following thrombolysis in acute ischaemic stroke...
  8. doi request reprint Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials
    Brett Cucchiara
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Stroke 40:3067-72. 2009
    ..A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies...
  9. pmc Evolution of the thrombolytic treatment window for acute ischemic stroke
    Andrew Stemer
    University of California, San Diego, Medical Office North, Third Floor, Suite 3, 200 West Arbor Drive, 8466, San Diego, CA, 92103, USA
    Curr Neurol Neurosci Rep 10:29-33. 2010
    ..5 h. This important finding hopefully will enable more patients to receive treatment and simultaneously provides an opportunity to reaffirm that the benefits of rt-PA diminish with time...
  10. pmc Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials
    Kennedy R Lees
    From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom K R L Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Nuffield Department of Population Health, University of Oxford, United Kingdom J E, L B, C B Statistics Department, Boehringer Ingelheim, Germany E B Melbourne Brain Centre, The Royal Melbourne Hospital and University of Melbourne, Australia S M D Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia G A D Mobile Stroke Unit and Stroke Research Program, Memorial Hermann Hospital, Houston, TX J C G Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland M K Department of Neuroradiology, Technische Universitat, Dresden, Germany R v K Stanford Stroke Center, Palo Alto, CA M G L Discipline of Medicine, Westmead Hospital Clinical School, George Institute For Global Health, University of Sydney, NSW, Australia R I L Department of Neurology, Cedars Sinai, Los Angeles, CA P L Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, United Kingdom G D M Centre for Clinical Brain Sciences, University of Edinburgh, Laboratory of Medical Immunology
    Stroke 47:2373-9. 2016
    ..Any improvement in functional outcome distribution has value, and herein we provide an assessment of the effect of alteplase on the distribution of the functional level by treatment delay, age, and stroke severity...
  11. doi request reprint Serum calcium as prognosticator in ischemic stroke
    Bruce Ovbiagele
    Stroke Center and Department of Neurology, University of California at Los Angeles Medical Center, 710 Westwood Plaza, Los Angeles, CA 90095, USA
    Stroke 39:2231-6. 2008
    ..Calcium (Ca(2+)) plays a role in the cellular and molecular pathways of ischemic neuronal death. We evaluated the impact of both early and delayed Ca(2+) levels on clinical outcomes from acute ischemic stroke...
  12. pmc Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models
    Patrick Lyden
    From the Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA
    Stroke 45:896-9. 2014
    ..We showed previously robust neuroprotection with the thrombin inhibitor argatroban and now sought additional support for its neuroprotective potential...
  13. doi request reprint The effect of transfer and hospital volume in subarachnoid hemorrhage patients
    Miriam Nuno
    Department of Neurosurgery, Cedars Sinai Medical Center, Center for Neurosurgical Outcomes Research, Maxine Dunitz Neurosurgical Institute, 8631 W Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Neurocrit Care 17:312-23. 2012
    ..Providers are often unclear about the safety of transferring critical patients. This study evaluated the "transfer effect" in a large sample of aneurysmal SAH patients undergoing treatment...
  14. doi request reprint Eagle syndrome revisited: cerebrovascular complications
    Tsuyoshi Todo
    Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Vasc Surg 26:729.e1-5. 2012
    ..Although rare, Eagle syndrome should be considered in the differential diagnosis in patients with cerebrovascular symptoms, especially those induced by positional change...
  15. doi request reprint Hematoma growth in oral anticoagulant related intracerebral hemorrhage
    Brett Cucchiara
    Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Stroke 39:2993-6. 2008
    ..Limited data suggest that intracerebral hemorrhage related to oral anticoagulant therapy (OAT ICH) is associated with more hemorrhage expansion and a worse prognosis than spontaneous ICH (SICH)...

Research Grants1

  1. Role of Angiogenesis Following Stroke
    Patrick Lyden; Fiscal Year: 2006
    ..abstract_text> ..